chevron_left
Drugs to Watch: Market Access in Focus- Eylea® HD

Addressing competitive challenges with a buy-and-bill strategy
Eylea HD is a high-dose version of aflibercept, a blockbuster drug for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and related conditions of the retina. Following FDA approval in August 2023, Regeneron released Eylea HD (8 mg) in anticipation of the 2025 expiration of its United States patent for Eylea (2 mg) in an effort to fend off competition from biosimilar drugs. Eylea HD may benefit from a “buy-and-bill” strategy and rebates that encourage providers to address competitive pricing pressures. This report explores:
- Disease and competitive landscape
- Pricing strategy
- Market size, share and growth
- Payer coverage
- Physician and patient perceptions